Diverging from traditional
target inhibition, proteasomal protein
degradation approaches have emerged as novel therapeutic modalities
that embody distinct pharmacological profiles and can access previously
undrugged targets. Small molecule degraders have the potential to
catalytically destroy target proteins at substoichiometric concentrations,
thus lowering administered doses and extending pharmacological effects.
With this mechanistic premise, research efforts have advanced the
development of small molecule degraders that benefit from stable and
increased affinity ternary complexes. However, a holistic framework
that evaluates different degradation modes from a catalytic perspective,
including focusing on kinetically favored degradation mechanisms,
is lacking. In this Outlook, we introduce the concept of an induced
cooperativity spectrum as a unifying framework to mechanistically
understand catalytic degradation profiles. This framework is bolstered
by key examples of published molecular degraders extending from molecular
glues to bivalent degraders. Critically, we discuss remaining challenges
and future opportunities in drug discovery to rationally design and
phenotypically screen for efficient degraders.